Business Wire

Pyramid Analytics Expands UK Presence With Launch of Public Sector Practice

15.9.2022 04:46:00 EEST | Business Wire | Press release

Share

Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, today announced the launch of a UK Public Sector Practice. The new division will bring the transformational power of augmented analytics to public departments, agencies and public bodies across the United Kingdom. Decision Intelligence enabled by AI and machine learning can modernize the delivery of critical public services, including healthcare, utilities, and transportation in Europe’s largest public sector market. There are 23 ministerial departments, 20 non-ministerial departments, 417 agencies and other public bodies, and 14 public corporations in the UK1.

Key Points:

  • The Guardian reported that UK government spending on technology R&D is estimated to reach £14.9 billion for 2021 and 2022, and the government aims to increase this to £22 billion by 2026–27.
  • The UK Public Sector practice will be led by Alastair Roriston, an experienced leader of successful programmes to connect technology with the needs of government agencies.
  • Pyramid has a long track record of enabling technology innovation in the public sector. Government customers include the United States Department of Veterans Affairs, Israel Aerospace Industries, Israel Defense Forces, Ministry of Defence of the Republic of Slovenia, and Statistics Finland.
  • The Pyramid Decision Intelligence Platform, training and services will be provided directly and through partnerships.
  • Decision Intelligence will help frontline public sector workers to make faster and more informed decisions, elevating the level of service for the general public.

A New Future for the UK Public Sector

The COVID-19 pandemic accelerated digital transformation across all sectors of the economy and society, and government needs to keep pace. Spearheaded with a clear mandate from Cabinet Office, the UK government is leading the way in reimagining how data can be used to improve the operations of the public sector and the standard of service they offer to ordinary people every day.

NHS England unveiled plans in April to develop a federated data platform (FDP), with an estimated procurement value of £240 million. According to the notice, the FDP will be “an ecosystem of technologies and services” and “an essential enabler to transformational improvements across the NHS”. It will be built around five major use cases: population health and person insight, care co-ordination, elective recovery, vaccines and immunisation, and the supply chain.

Pyramid Experience with Massive Public Healthcare Systems

The Pyramid Decision Intelligence Platform is currently used by the United States Department of Veteran Affairs (VA), a Cabinet-level executive branch department of the federal government charged with providing life-long healthcare services to eligible military veterans at the 170 medical centers and outpatient clinics located throughout the country. The VA provides comprehensive healthcare services to 9 million veterans.

The Pyramid Decision Intelligence Platform is used by clinical, medical and administrative staff to identify patterns and execution gaps across the system, ensuring US military veterans receive more personalised and enhanced care. So far, a programme run by just three people has trained 40,000 staff in the use of the platform, with plans to eventually equip 60,000 to start using Decision Intelligence to improve the services they offer to US military veterans and their families.

Decision Intelligence is the Next Big Data Analytics Innovation

The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.

The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.

Quotes

Tom Warren , Regional Managing Director, UKI, Pyramid Analytics:

“The Pyramid family are excited to announce this next chapter of our story. We look forward to enabling the digital transformation of UK public sector organisations, helping to deliver better, faster and more efficient services to those who need them the most. We hope to use Decision Intelligence to turn data analytics in the public sector from the complex to the simple with decision intelligence.

“I am excited to be working with the highly experienced and forward-thinking Alastair Roriston to advance Pyramid’s expansion into the UK public sector. He joins an already successful and high-performing team, who have been instrumental to Pyramid’s expansion in the UKI. With Alastair’s expertise, the sky is the limit.”

Alastair Roriston , Director of Sales UK Public Sector, Pyramid Analytics:

“I am thrilled to have joined this innovative and ground-breaking company and even keener to assist in its expansion into the UK public sector. Throughout my career, I have seen the huge positive impact when the essential work of the public sector is married to the cutting-edge possibilities of technology – the opportunity for change is nearly limitless.

“I truly believe that Pyramid’s decision intelligence platform will revolutionise how government and public sector organisations deliver their digital and online services. Far too often, the wheels of public services are held up by siloed systems and antiquated approaches to data. A doctor should not have to wait precious minutes or hours for reports and patient data to arrive. Why should they not have that information and advice on next steps available in moments? Decision intelligence can eliminate these inefficiencies, making every frontline public sector worker a citizen data scientist with a world of dynamic, augmented analytics at their fingertips.”

About Pyramid Analytics

Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.

Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Learn more at Pyramid Analytics.

1 GOV.UK

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

UK
Alex Izza
Resonance
+44 (0) 759 189 9654
pyramidanalytics@resonancecrowd.com

US
Heather Racicot
Resonance
+1 360-632-5616
pyramidanalytics@resonancecrowd.com

Chas Kielt
Vice President of Global Corporate Communications, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye